Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule PURPOSE: Platinum-based ...

Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study This is an ASCO Meeting Abstract from the ...

At its May 30 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) endorsed the approval of several cancer therapies. The drug review panel ...

Immunotherapy improved overall survival when added to cisplatin-gemcitabine but not when added to carboplatin-gemcitabine. Adding immunotherapy to platinum-gemcitabine chemotherapy can improve ...

Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...